Table 1.
Baseline characteristics.
| Group 1 (treatment only) (n=10) | Group 2 (treatment and control) (n=8) | All patients (n=18) | p-value Group 1 vs Group 2 | |
|---|---|---|---|---|
| Age (in years) | 46 ± 17 | 44 ± 17 | 45 ± 17 | 0.73 |
| Sex | 7 female/3 male | 7 female/1 male | 14 female/4 male | |
| Cause of hyperthyroidism | - 9 Graves’ disease - 1 overtreatment |
- 6 Graves’ disease - 2 subacute thyreoiditis |
- 15 Graves’ disease - 2 subacute thyreoiditis - 1 overtreatment |
|
|
Hyperthyroidism symptom scale
(total points) |
14 ± 8 | 14 ± 6.0 | 14 ± 7 | 0.97 |
| Weight (kg) | 69 ± 21 | 66 ± 15 | 67 ± 18 | 0.71 |
| Height (cm) | 170 ± 10 | 165 ± 7.4 | 168 ± 9.4 | 0.26 |
| BMI (kg/m2) | 24 ± 5 | 24 ± 4 | 24 ± 4.5 | 0.80 |
| Pulse rate 0 min Pulse rate 90 min after Propranolol |
81 ± 9.2 67 ± 9.5*** p= 0.0007 |
81 ± 16 67 ± 5.9* p= 0.0137 |
81 ± 12 67 ± 7.7**** p <0.0001 |
0.99 0.93 |
| Systolic blood pressure (mmHg) | 127 ± 18 | 129 ± 16 | 128 ± 16 | 0.74 |
| Diastolic blood pressure (mmHg) | 74 ± 13 | 69 ± 7.6 | 72 ± 11 | 0.43 |
| TSH (mlU/L, Ref. 0.332-4.490mIU/l) | 0.0079 ± 0.0078 | 0.007 ± 0.0042 | 0.0075 ± 0.0063 | 0.78 |
| free T4 (pmol/l, Ref. 11.9-21.6pmol/l) | 38 ± 24 | 33 ± 9.7 | 36 ± 18 | 0.60 |
| free T3 (pmol/l, Ref. 2.6-5.6pmol/l) | 11 ± 5.6 | 11 ± 5.3 | 11 ± 5.3 | 0.94 |
| REE Before Propranolol REE Before Control |
1717 ± 320 - |
1541 ± 280 1540 ± 272 |
1639 ± 307 - |
0.24 N/A |
*p < 0.05, ***p < 0.001, ****p < 0.0001. N/A= not applicable.